Subversive Images and Forgotten Truths: A Selected Visual History of Black Women Religious

2016 ◽  
Vol 127 (3) ◽  
pp. 93-103
Author(s):  
Shannen Dee Williams
2021 ◽  
Vol 33 (4) ◽  
pp. 557-576
Author(s):  
Laura Engel

Contemporary artists Elizabeth Colomba and Fabiola Jean-Louis employ eighteenth-century subject matter, iconography, and media to reimagine the visual history of Black women. Putting Colomba’s and Jean-Louis’s work in dialogue with my own, I return to the premises of my book Women, Performance, and the Material of Memory: The Archival Tourist (2019), to re-examine, interrogate, and acknowledge my position as a white scholar.


Costume ◽  
2017 ◽  
Vol 51 (2) ◽  
pp. 247-253
Author(s):  
Naomi E. A. Tarrant
Keyword(s):  

2020 ◽  
Vol 39 (1) ◽  
pp. 169-184
Author(s):  
Ana Olivarez-Levinson ◽  
Eric Mayer-García
Keyword(s):  

2021 ◽  
pp. ijgc-2021-002753
Author(s):  
J Stuart Ferriss ◽  
Britt K Erickson ◽  
Ie-Ming Shih ◽  
Amanda N Fader

The incidence and mortality rates from endometrial cancer continue to increase worldwide, while rates in most other cancers have either plateaued or declined considerably. Uterine serous carcinoma represents a fraction of all endometrial malignancies each year, yet this histology is responsible for nearly 40% of all endometrial cancer-related deaths. These deaths disproportionately affect black women, who have higher rates of advanced disease at diagnosis. Molecular genetic analyses reveal major alterations including TP53 mutation, PIK3CA mutation/amplification, ERBB2 amplification, CCNE1 amplification, FBXW7 mutation/deletion, PPP2R1A mutation, and somatic mutations involving homologous recombination genes. Clinical risk factors for uterine serous carcinoma include advancing age, a history of breast cancer, tamoxifen usage, and the hereditary breast–ovarian cancer syndrome. Surgery remains the cornerstone of treatment. Recent advances in our understanding of uterine serous carcinoma molecular drivers have led to development of targeted therapeutics that promise improved outcomes for patients. Overexpression or amplification of HER2 in uterine serous carcinoma carries a poor prognosis; yet this actionable target has led to the incorporation of several anti-HER2 therapies, including trastuzumab which, when added to conventional chemotherapy, is associated with improved survival for women with advanced and recurrent HER2-positive disease. The combination of pembrolizumab and lenvatinib is also a promising targeted treatment strategy for women with uterine serous carcinoma, with a recent phase II study suggesting a 50% response rate in women with recurrent disease. Several trials examining additional targeted agents are ongoing. Despite years of stalled progress, meaningful, tailored treatment options are emerging for patients with this uncommon and biologically aggressive endometrial cancer subtype.


1974 ◽  
Vol 8 (3) ◽  
pp. 319-337 ◽  
Author(s):  
Ann Massa

The scope of the Chicago World's Fair of 1893, which celebrated, albeit a year late, the four hundredth anniversary of Columbus's discovery of America, ranged over many centuries, numerous nations and almost every type of human achievement. The 27 million people who came to the five months long Fair were able to see Grace Darling's boat or Spanish galleons of Columbus's time; they could follow the history of transport from coracles to cars; they could see the latest in Krupp's cannon and Bell's telephone in a classically styled Machinery Hall six times the size of the Coliseum. With the exception of Louis Sullivan's golden Transportation Pavilion, the buildings which housed the Fair, covered uniformly with staff, composed a classical ‘White City’, grouped round a complex of lagoons and fountains on Chicago's Lake Front.


Sign in / Sign up

Export Citation Format

Share Document